KDR and adrenocortical carcinoma, hereditary: Ferrarotto et al. recently conducted a phase II trial evaluating the efficacy of VEGFR inhibitor axitinib and PD-L1 inhibitor avelumab in patients with recurrent/metastatic AdCC.